Literature DB >> 8683381

Expression of platelet-derived growth factor (PDGF) and PDGF receptors in human malignant mesothelioma in vitro and in vivo.

A W Langerak1, P A De Laat, C A Van Der Linden-Van Beurden, M Delahaye, T H Van Der Kwast, H C Hoogsteden, R Benner, M A Versnel.   

Abstract

The expression of platelet-derived growth factor (PDGF) and PDGF receptors was studied in human normal and malignant mesothelial cells in vitro and in vivo. Staining with anti-cytokeratin and ME1 antibodies and ultrastructural analysis confirmed the mesothelial nature of the cell lines used to study PDGF and PDGF receptor expression in vitro. Using antibodies, mesothelioma cell lines were found to express PDGF and both the PDGF alpha- and the PDGF beta-receptor, whereas cultured normal mesothelial cells expressed PDGF and PDGF alpha-receptor. This PDGF and PDGF receptor staining pattern largely reflects the earlier described mRNA expression in these cell lines. The only exception was the immunocytochemical detection of PDGF alpha-receptors in the mesothelioma cell lines, which is different from the inability to detect alpha-receptor transcripts on Northern blots. Expression was also investigated in mesothelial cells in vivo. Expression of PDGF was observed in malignant mesothelioma cells on frozen tissue sections. In pleural effusions, a double immunofluorescence staining procedure for PDGF and epithelial membrane antigen (EMA) revealed PDGF expression by EMA-positive malignant mesothelioma cells. PDGF beta-receptors and occasionally PDGF alpha-receptors were detected in frozen tissue sections of malignant mesotheliomas, whereas mesothelioma cells in effusions showed faint expression of only the PDGF beta-receptor. In contrast, in effusions containing non-malignant mesothelial cells, only a very low level of PDGF alpha-receptor could be detected. Taken together, these results indicate that the pattern of PDGF and PDGF receptor expression in mesothelial cells in vivo largely corresponds to expression of PDGF and its receptors in vitro. Malignant mesothelioma cell lines thus constitute a good model system for studies on the role of PDGF in this malignancy. Furthermore, the data reported in this paper are consistent with the idea that an autocrine growth stimulatory effect of PDGF via PDGF receptors may play a role in the pathogenesis of malignant mesothelioma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8683381     DOI: 10.1002/(SICI)1096-9896(199602)178:2<151::AID-PATH425>3.0.CO;2-E

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  17 in total

Review 1.  Novel systemic therapy against malignant pleural mesothelioma.

Authors:  Michael R Mancuso; Joel W Neal
Journal:  Transl Lung Cancer Res       Date:  2017-06

2.  Immunological alterations found in mesothelioma patients and supporting experimental evidence.

Authors:  Yoshie Miura; Yasumitsu Nishimura; Megumi Maeda; Shuko Murakami; Hiroaki Hayashi; Kazuya Fukuoka; Takumi Kishimoto; Takashi Nakano; Takemi Otsuki
Journal:  Environ Health Prev Med       Date:  2008-02-28       Impact factor: 3.674

3.  The selection of peritoneal mesothelial cells is important for cell therapy to prevent peritoneal fibrosis.

Authors:  Shinji Kitamura; Naoya Horimoto; Kenji Tsuji; Akiko Inoue; Keiichi Takiue; Hitoshi Sugiyama; Hirofumi Makino
Journal:  Tissue Eng Part A       Date:  2013-12-03       Impact factor: 3.845

4.  Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905).

Authors:  Anne S Tsao; James Moon; Ignacio I Wistuba; Nicholas J Vogelzang; Gregory P Kalemkerian; Mary W Redman; David R Gandara; Karen Kelly
Journal:  J Thorac Oncol       Date:  2017-06-06       Impact factor: 15.609

5.  Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).

Authors:  Thierry Jahan; Lin Gu; Robert Kratzke; Arkadiusz Dudek; Gregory A Otterson; Xiaofei Wang; Mark Green; Everett E Vokes; Hedy Lee Kindler
Journal:  Lung Cancer       Date:  2011-12-22       Impact factor: 5.705

6.  Immunological changes in mesothelioma patients and their experimental detection.

Authors:  Megumi Maeda; Yoshie Miura; Yasumitsu Nishimura; Shuko Murakami; Hiroaki Hayashi; Naoko Kumagai; Tamayo Hatayama; Minako Katoh; Naomi Miyahara; Shoko Yamamoto; Kazuya Fukuoka; Takumi Kishimoto; Takashi Nakano; Takemi Otsuki
Journal:  Clin Med Circ Respirat Pulm Med       Date:  2008-03-26

7.  Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma.

Authors:  Anne S Tsao; Nusrat Harun; Junya Fujimoto; Vikki Devito; J Jack Lee; Elisabetta Kuhn; Reza Mehran; David Rice; Cesar Moran; Waun Ki Hong; Li Shen; Milind Suraokar; Ignacio Wistuba
Journal:  Ann Diagn Pathol       Date:  2014-02-20       Impact factor: 2.090

8.  Platelet-derived growth factor (PDGF) BB acts as a chemoattractant for human malignant mesothelioma cells via PDGF receptor beta-integrin alpha3beta1 interaction.

Authors:  J Klominek; B Baskin; D Hauzenberger
Journal:  Clin Exp Metastasis       Date:  1998-08       Impact factor: 5.150

9.  Targeting c-KIT, PDGFR in cancer of unknown primary: a screening study for molecular markers of benefit.

Authors:  L Dova; G Pentheroudakis; V Golfinopoulos; V Malamou-Mitsi; I Georgiou; G Vartholomatos; A Ntemou; G Fountzilas; N Pavlidis
Journal:  J Cancer Res Clin Oncol       Date:  2007-12-07       Impact factor: 4.553

Review 10.  Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies.

Authors:  Angela Bononi; Andrea Napolitano; Harvey I Pass; Haining Yang; Michele Carbone
Journal:  Expert Rev Respir Med       Date:  2015-08-26       Impact factor: 3.772

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.